Galaxy Medicare (NSE:GML) Research & Development: ₹0.0 Mil (TTM As of Mar. 2026)


NSE:GML Galaxy Medicare Ltd NSE:GML
19 GF Score
Price ₹17.85
! 2 Warning Signs
View Full Analysis

What is Galaxy Medicare Research & Development?

Galaxy Medicare NSE:GML -3.51% 19 Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus rates NSE:GML with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Galaxy Medicare's Research & Development for the six months ended in Mar. 2026 was ₹0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.0 Mil.

Galaxy Medicare  (NSE:GML) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Galaxy Medicare Research & Development Related Terms

Galaxy Medicare Research & Development Historical Data

* Premium members only.

The historical data trend for Galaxy Medicare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galaxy Medicare Research & Development Chart

Galaxy Medicare Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
0.00 0.00 0.00 0.00 0.00

Galaxy Medicare Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
NSE:GML
19GF Score
Galaxy Medicare Ltd NSE:GML
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galaxy Medicare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0.0 Mil mean?
Galaxy Medicare (NSE:GML) has a Research & Development of ₹0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Galaxy Medicare and its competitors.
Is Galaxy Medicare's Research & Development too high?
Galaxy Medicare's current Research & Development is ₹0.0 Mil. Overall, Galaxy Medicare has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Galaxy Medicare's Research & Development compare to ISRG and BDX?
Galaxy Medicare's Research & Development of ₹0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Galaxy Medicare and its competitors. Galaxy Medicare's current Research & Development is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galaxy Medicare stock overvalued right now?
Galaxy Medicare (NSE:GML) has a current Research & Development of ₹0.0 Mil. The current Research & Development is ₹0.0 Mil. Galaxy Medicare's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Galaxy Medicare (NSE:GML), the current Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galaxy Medicare Business Description

Address Plot No-2, Zone D, Phase A, Mancheswar Industrial Estate, Khurda, Bhubaneswar, OR, IND, 751010
Galaxy Medicare Ltd is engaged into the manufacturing, trading and exporting of Medical Devices, Plasters of Paris Bandages (POP Bandage) and Other surgical dressings in India. Its business encompass: Manufacturing and Branding of its own products under its flagship brands i.e. POP BAND, POP CAST, G CAST, GYPSOSOFT, GYPSOPLAST, CARETAPE, GYPSOCREPE, CARECREPE, CAREPORE GYPSONET, GYPSOCHLOR, FIXCAN ETC.
19GF Score

Get the complete analysis for NSE:GML

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹17.85
Price